Prev Close | 84.01 |
Open | 83.99 |
Day Low/High | 83.62 / 84.74 |
52 Wk Low/High | 69.18 / 99.84 |
Volume | 1.92M |
Avg Volume | 1.84M |
Prev Close | 84.01 |
Open | 83.99 |
Day Low/High | 83.62 / 84.74 |
52 Wk Low/High | 69.18 / 99.84 |
Volume | 1.92M |
Avg Volume | 1.84M |
Exchange | NYSE |
Shares Outstanding | 2.47B |
Market Cap | 217.73B |
EPS | 3.10 |
P/E Ratio | 30.86 |
Div & Yield | 2.01 (2.29%) |
Dividend yield is the determining factor in this strategy.
U.S. futures are down ahead of the final day of the Fed's 2-day policy meeting on Wednesday.
The WEF host country has a lot to offer to investors.
Small biotech plunged in July, but has stabilized on two key deals.
Underlying support for stock prices remains positive, especially if oil prices stabilize near current levels and the dollar does not rise a lot further.
Healthcare stocks were hit hard in the third quarter after leading the S&P 500 for the first half of the year.
And four other things you need to know now.
Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.
Here are some of the best pharmaceuticals our algorithm says you should consider looking at.
Here are some of the best pharmaceutical companies, that pay high dividends, TheStreet Quant Ratings says you should consider looking at.
European markets rose Wednesday after European leaders gave Greece a Sunday ultimatum for a final rescue deal or face eviction from the single currency.
Don't rely on Europe; it's too out of sync with U.S.
In this era of turmoil, investors can take comfort in this sector.
Whether it's acquiring or the acquired, Mylan is building shareholder value.
Let's take a little tour through the various equity asset classes.
Americans are living much longer these days -- and there are a number of ways to invest.
A selection based on James P. O'Shaughnessy's strategy.
Some of the most well-known American brands aren't actually so American, after all.
Investors will be tracking Pfizer's earnings when they report first-quarter results on May 5. Expectations are for earnings of $0.55 a share on sales of $12.07 billion.
Futures point higher; blockbuster drug deal boosts European markets.
Update: Futures positive as quarter closes; J&J sells ortho unit.
Array is partnering with AstraZeneca and Novartis on a number of cancer drugs with trials soon getting underway that could transform the company by year end.
When investing beyond your own shores, choose value over growth.
Some European names look ripe for investment right now.
Let's take a peek at overnight and early-morning price action in the major asset classes. Exit light Enter night Take my hand We're off to never never land. -- Metallica, "Enter Sandman" Let's take a peek at overnight and early-morning price action ...
Two domestic exploration and production names that scream 'buy me' are Devon and Southwestern.
Now is the time to pop the pharmaceutical pill and buy.
A look at the day's most searched trends on the Web, including UBS after the Swiss bank posted a worse-than-expected second-quarter profit due to losses it incurred from the Facebook initial public offering.
IRM has been trading in a declining triangle pattern since July. Technical indications of NVS are also positive.